Profund Advisors LLC Buys 53,697 Shares of Elanco Animal Health Incorporated $ELAN

Profund Advisors LLC grew its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 239.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,116 shares of the company’s stock after purchasing an additional 53,697 shares during the quarter. Profund Advisors LLC’s holdings in Elanco Animal Health were worth $1,704,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ELAN. BlackRock Inc. bought a new stake in shares of Elanco Animal Health during the 2nd quarter valued at about $1,202,198,000. Squarepoint Ops LLC purchased a new stake in shares of Elanco Animal Health in the second quarter valued at about $3,279,000. State Street Corp grew its stake in Elanco Animal Health by 4.7% in the 2nd quarter. State Street Corp now owns 16,063,046 shares of the company’s stock valued at $395,312,000 after purchasing an additional 726,567 shares during the period. S&CO Inc. purchased a new stake in Elanco Animal Health during the second quarter worth about $2,738,000. Finally, Artemis Investment Management LLP lifted its stake in Elanco Animal Health by 55.5% in the third quarter. Artemis Investment Management LLP now owns 4,611,977 shares of the company’s stock valued at $103,262,000 after purchasing an additional 1,645,331 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Timothy Bettington sold 4,350 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the transaction, the insider owned 138,911 shares in the company, valued at approximately $3,194,953. This represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lawrence Kurzius acquired 40,000 shares of the stock in a transaction on Thursday, August 20th. The shares were bought at an average price of $23.40 per share, with a total value of $936,000.00. Following the purchase, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. The trade was a 26.91% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 63,198 shares of company stock worth $1,473,109. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. UBS Group lifted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Finally, The Goldman Sachs Group assumed coverage on shares of Elanco Animal Health in a research note on Friday, October 16th. They issued a “buy” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.33.

Elanco Animal Health Stock Up 4.2%

Shares of NYSE ELAN opened at $24.03 on Tuesday. Elanco Animal Health Incorporated has a 52 week low of $19.40 and a 52 week high of $27.98. The business has a 50-day simple moving average of $23.13 and a two-hundred day simple moving average of $23.82. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company has a market cap of $12.01 billion, a P/E ratio of -58.62, a P/E/G ratio of 2.01 and a beta of 1.70.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same quarter last year, the company earned $0.26 earnings per share. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts anticipate that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.